Research Article
The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
Table 1
Demographic and clinical features of the study sample (
).
| Baseline characteristics | | Gender, (%) | | Women | 18 (35%) | Men | 33 (65%) | Age, years | | Mean (SD) | 61.7 (12.9) | Median (range) | 62 (25–84) | MGMT methylation, % | | Mean (SD) | 21.5 (19.1) | Median (range) | 16 (2–85) | Treatment history | | Surgery, (%) | | Done | 46 (90%) | Not done | 5 (10%) | Radiotherapy, (%) | | Done | 39 (76%) | Not done | 12 (24%) | Chemotherapy, (%) | | Done | 41 (80%) | Not done | 10 (20%) | Main outcomes | | Overall survival, (%) | | Dead | 24 (47%) | Alive | 27 (53%) | Progression-free survival | | Progressed | 34 (67%) | Not progressed | 17 (23%) | Follow-up time, months | | Mean (SD) | 11.9 (6.8) | Median (range) | 12 (3–27) |
|
|
Follow-up time refers to time from disease diagnosis and death or last visit.
|